Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The trial investigates the safety and efficacy of irreversible electroporation in combination
with checkpoint inhibition in patients with metastatic pancreatic cancer.